依曲莫德治疗斑秃的疗效与安全性:一项多中心随机双盲安慰剂对照2期研究
这项2期随机双盲安慰剂对照试验纳入80例中重度斑秃成人患者,评估口服依曲莫德2 mg或3 mg与安慰剂的疗效。第24周时,依曲莫德2 mg和3 mg组SALT评分较基线的变化百分比与安慰剂组差异均未达统计学显著(P=0.2579和P=0.0592),未达到主要终点,但数值上高于安慰剂组,安全性良好,该适应症临床项目已终止。
要点
- 依曲莫德2 mg和3 mg组第24周SALT评分变化百分比与安慰剂差异无统计学意义。
- 依曲莫德组达到SALT改善≥30%、≥50%、≥75%的患者比例数值上高于安慰剂组。
- 依曲莫德耐受性良好,安全性与其他依曲莫德研究一致,斑秃项目已终止。
核心结论
- 依曲莫德未达到主要和次要疗效终点,但疗效在数值上高于安慰剂。
- 依曲莫德临床项目针对斑秃已终止。
- 依曲莫德耐受性良好,安全性特征与其他依曲莫德研究一致。
研究设计与样本
- 2期、随机、双盲、安慰剂对照试验,纳入年龄≥18岁、SALT评分≥25的中重度斑秃患者。
- 患者序贯入组两个队列:队列1(SALT≥50)按2:1随机分配至依曲莫德2 mg或安慰剂;队列2(SALT≥25且<95)按4:1:2随机分配至依曲莫德3 mg、2 mg或安慰剂。
- 共80例患者随机分配至依曲莫德2 mg(n=31)、3 mg(n=25)或安慰剂(n=24),完成24周双盲期和28周开放标签延长期。
- 主要终点为第24周SALT评分较基线的变化百分比(%CFB)。
主要发现
- 第24周时,依曲莫德2 mg、3 mg和安慰剂组SALT评分%CFB的最小二乘均值(SE)分别为-13.8(8.6)、-21.4(6.9)和0.35(8.9)。
- 依曲莫德2 mg与安慰剂相比,SALT评分%CFB的最小二乘均值差异(95%CI;P值)为-14.1(-38.9至10.6;P=0.2579)。
- 依曲莫德3 mg与安慰剂相比,SALT评分%CFB的最小二乘均值差异(95%CI;P值)为-21.8(-44.4至0.9;P=0.0592)。
- 第24周达到SALT评分较基线改善≥30%、≥50%或≥75%的患者比例,依曲莫德组普遍在数值上高于安慰剂组。
- 截至第24周,依曲莫德2 mg、3 mg和安慰剂组治疗中出现的不良事件发生率分别为67.7%、80.0%和78.3%。
关键数值与推荐
- 中重度斑秃定义为SALT评分≥25。
- 主要终点第24周SALT评分%CFB未达统计学优效。
临床怎么用
- 依曲莫德2 mg和3 mg未显示统计学显著优于安慰剂的疗效,不推荐用于中重度斑秃的常规治疗。
- 该药物在斑秃中的临床开发已终止,临床决策应基于其他有证据的治疗方案。
局限性
- 样本量较小(共80例),可能影响统计效能。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Etrasimod, an oral, selective sphingosine 1-phosphate 1, 4 and 5 receptor modulator approved for the treatment of ulcerative colitis, has been studied in immune-mediated inflammatory diseases, including alopecia areata (AA). OBJECTIVES: To evaluate the efficacy and safety of etrasimod in adults with moderate to severe AA. METHODS: This Phase 2, randomized, double-blind, placebo-controlled trial included patients (aged ≥18 years) with moderate to severe AA, defined as a Severity of Alopecia Tool (SALT) score of ≥25. Patients were sequentially enrolled into two cohorts. Cohort 1 included patients (SALT score of ≥50) randomized 2:1 to etrasimod 2 mg or placebo. Cohort 2 included patients (SALT score ≥25 to <95) randomized 4:1:2 to etrasimod 3 mg, 2 mg or placebo. Patients completed a 24-week double-blind and 28-week open-label extension period. The primary endpoint was percent change from baseline (%CFB) in SALT score at Week 24. Safety was monitored throughout the trial. RESULTS: Eighty patients were randomized to etrasimod 2 mg (n = 31), 3 mg (n = 25) or placebo (n = 24). At Week 24, least squares mean (SE) percent changes from baseline in SALT score for the etrasimod 2 mg, 3 mg and placebo groups were -13.8 (8.6), -21.4 (6.9) and 0.35 (8.9), respectively. The least squares mean difference (95% CI; P value) in SALT score %CFB of etrasimod 2 mg and 3 mg versus placebo was -14.1 (-38.9 to 10.6; p = 0.2579) and - 21.8 (-44.4 to 0.9; p = 0.0592), respectively; statistical superiority was not achieved. The proportions of patients achieving ≥30%, ≥50% or ≥75% improvement in baseline SALT score at Week 24 were generally numerically higher in etrasimod groups versus placebo. Treatment-emergent adverse events occurred in 67.7%, 80.0% and 78.3% of patients receiving etrasimod 2 mg, 3 mg and placebo, respectively, by Week 24. CONCLUSIONS: Etrasimod did not meet the primary and secondary efficacy endpoints, but efficacy was numerically higher with etrasimod than with placebo. The etrasimod clinical programme for AA has been discontinued. Etrasimod was well tolerated, and its safety profile was consistent with other etrasimod studies to date. TRIAL REGISTRATION: ClinicalTrials.gov: NCT04556734.
引用
- King B, Mesinkovska N, Senna M, et al. Efficacy and safety of etrasimod in alopecia areata: A multicentre, randomized, double-blind, placebo-controlled, Phase 2 study. J Eur Acad Dermatol Venereol. 2025. PMID: 40145547. doi:10.1111/jdv.20605
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。